Novartis Zelmac Well Tolerated In Alternating IBS, Study Suggests
Executive Summary
Novartis' constipation-predominant irritable bowel syndrome therapy Zelmac is well tolerated in patients with alternating IBS, data presented at the United European Gastroenterology Week in Brussels Nov. 28 suggests.
You may also be interested in...
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Glaxo Wellcome's withdrawal of Lotronex suggests that hurdles remain in FDA's efforts to expand the use of risk management programs for approved products.
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Glaxo Wellcome's withdrawal of Lotronex suggests that hurdles remain in FDA's efforts to expand the use of risk management programs for approved products.
Novartis Zelmac Dosing Instructions Among Remaining Issues In FDA Review
FDA will have to decide between a high dose or titrated regimen for Novartis' irritable bowel syndrome therapy Zelmac following a review by the Gastrointestinal Drugs Advisory Committee.